| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Membrane lipid remodeling (DGLA incorporation) |
↑ substrate (context-dependent) |
↑ membrane incorporation |
G |
Phospholipid composition shift |
Changes membrane fluidity and eicosanoid substrate pool; time-dependent remodeling. |
| 2 |
Eicosanoid balance (PGE1 vs AA-derived eicosanoids) |
↔ / ↓ pro-inflammatory tone |
↓ inflammation |
G |
Anti-inflammatory modulation |
DGLA-derived PGE1 often anti-inflammatory; may counterbalance arachidonic acid metabolites. |
| 3 |
ROS / Lipid peroxidation |
↑ (PUFA-dependent; dose-dependent) |
↔ / ↑ (high dose) |
P/R |
Lipid oxidative susceptibility |
Highly unsaturated structure increases peroxidation potential; may sensitize tumors to oxidative stress. |
| 4 |
NF-κB |
↓ (context-dependent) |
↓ |
R/G |
Reduced inflammatory transcription |
Often secondary to altered eicosanoid signaling. |
| 5 |
PPAR (α/γ) |
↑ (model-dependent) |
↑ |
R/G |
Lipid metabolic regulation |
GLA and derivatives may activate PPAR pathways influencing lipid and glucose metabolism. |
| 6 |
Apoptosis |
↑ (high concentration only) |
↔ |
R/G |
Mitochondrial apoptosis (experimental) |
Reported in certain tumor lines at supra-physiologic levels. |
| 7 |
Ferroptosis |
↑ (theoretical; PUFA-linked) |
↔ |
R/G |
Lipid peroxidation vulnerability |
PUFA enrichment can enhance ferroptotic susceptibility depending on antioxidant context. |
| 8 |
HIF-1α |
↔ (limited evidence) |
↔ |
G |
Not primary axis |
No consistent direct modulation reported. |
| 9 |
NRF2 |
↔ / ↑ (adaptive; context-dependent) |
↔ |
R/G |
Redox-response adjustment |
May activate antioxidant response secondary to lipid peroxidation stress. |
| 10 |
Ca²⁺ signaling |
↔ (membrane-dependent) |
↔ |
P/R |
Membrane microdomain modulation |
Changes in lipid composition can subtly influence ion channel behavior. |
| 11 |
Clinical Translation Constraint |
↓ (constraint) |
↓ (constraint) |
— |
Context-dependent effects |
Physiologic doses primarily anti-inflammatory; anti-cancer cytotoxicity not clinically established. |